Director, Corporate Counsel

Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's.

The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) - both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration-directed trials across Non-Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST.

In July 2025, Cogent announced that its registration-direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top-line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025.

The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.

Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights.

This is a broad, hands-on role for a n attorney who will join a growing legal department and serve as counsel in connection with various types of contracts supp o rting business needs, including strategic transactio ns, research collaborations, services arrangements and other legal needs as the company transitions into a commercial-stage biotech company and its other pipeline programs evolve. The Corporate Counsel will partner closely with cross-functional teams to support transactional matters , including drafting, reviewing, and negotiating a portfolio of agreements;

advising internal clients on strategic business development projects ; and ensuring compliance with applicable laws , while helping mitigate legal risk and enable business growth in a fast-paced biotechnology environment . Reporting to the Associate General Counsel, this position will work with multiple functional areas and assist on a broad range of legal matters across the organization.

• Draft, review, negotiate, and manage a wide variety of agreements, including confidentiality agreements, master service agreements, statements of work, sponsorship agreements,consulting agreements, clinical trial agreements, vendor and supplier agreements,collaboration and licensing agreements, and sponsored research agreements.
• Collaborate with colleagues across commercial, medical affairs, research, clinical operations, finance, and senior leadership toprovidebusiness-focused legal advice that balances risk with company objectives.
• Monitor changes in applicable laws and regulations and…